NCT01479842View on ClinicalTrials.gov

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 26, 2014

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2026

Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaSplenic Marginal Zone LymphomaWaldenstrom Macroglobulinemia
Interventions
DRUG

BTK inhibitor PCI-32765

Given PO

BIOLOGICAL

rituximab

Given IV

DRUG

bendamustine hydrochloride

Given IV

OTHER

pharmacogenomic studies

Correlative studies

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

43210

Ohio State University Medical Center, Columbus

Sponsors

Collaborators (1)

Pharmacyclics LLC.
All Listed Sponsors
collaborator

Pharmacyclics LLC.

INDUSTRY

lead

Kami Maddocks, MD

OTHER